Skip to main content

Chondroitin Sulfate Inhibits Monocyte Chemoattractant Protein-1 Release From 3T3-L1 Adipocytes: A New Treatment Opportunity for Obesity-Related Inflammation?

Publication ,  Journal Article
Stabler, TV; Montell, E; Vergés, J; Huebner, JL; Kraus, VB
Published in: Biomark Insights
2017

Monocyte chemoattractant protein-1 (MCP-1) overproduction from inflamed adipose tissue is a major contributor to obesity-related metabolic syndromes. 3T3-L1 embryonic fibroblasts were cultured and differentiated into adipocytes using an established protocol. Adipocytes were treated with lipopolysaccharide (LPS) to induce inflammation and thus MCP-1 release. At the same time, varying concentrations of chondroitin sulfate (CS) were added in a physiologically relevant range (10-200 µg/mL) to determine its impact on MCP-1 release. Chondroitin sulfate, a natural glycosaminoglycan of connective tissue including the cartilage extracellular matrix, was chosen on the basis of our previous studies demonstrating its anti-inflammatory effect on macrophages. Because the main action of MCP-1 is to induce monocyte migration, cultured THP-1 monocytes were used to test whether CS at the highest physiologically relevant concentration could inhibit cell migration induced by human recombinant MCP-1. Chondroitin sulfate (100-200 µg/mL) inhibited MCP-1 release from inflamed adipocytes in a dose-dependent manner (P < .01, 95% confidence interval [CI]: -5.89 to -3.858 at 100 µg/mL and P < .001, 95% CI: -6.028 to -3.996 at 200 µg/mL) but had no effect on MCP-1-driven chemotaxis of THP-1 monocytes. In summary, CS could be expected to reduce macrophage infiltration into adipose tissue by reduction in adipocyte expression and release of MCP-1 and as such might reduce adipose tissue inflammation in response to pro-inflammatory stimuli such as LPS, now increasingly recognized to be relevant in vivo.

Duke Scholars

Published In

Biomark Insights

DOI

ISSN

1177-2719

Publication Date

2017

Volume

12

Start / End Page

1177271917726964

Location

United States

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3205 Medical biochemistry and metabolomics
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stabler, T. V., Montell, E., Vergés, J., Huebner, J. L., & Kraus, V. B. (2017). Chondroitin Sulfate Inhibits Monocyte Chemoattractant Protein-1 Release From 3T3-L1 Adipocytes: A New Treatment Opportunity for Obesity-Related Inflammation? Biomark Insights, 12, 1177271917726964. https://doi.org/10.1177/1177271917726964
Stabler, Thomas V., Eulàlia Montell, Josep Vergés, Janet L. Huebner, and Virginia Byers Kraus. “Chondroitin Sulfate Inhibits Monocyte Chemoattractant Protein-1 Release From 3T3-L1 Adipocytes: A New Treatment Opportunity for Obesity-Related Inflammation?Biomark Insights 12 (2017): 1177271917726964. https://doi.org/10.1177/1177271917726964.
Stabler, Thomas V., et al. “Chondroitin Sulfate Inhibits Monocyte Chemoattractant Protein-1 Release From 3T3-L1 Adipocytes: A New Treatment Opportunity for Obesity-Related Inflammation?Biomark Insights, vol. 12, 2017, p. 1177271917726964. Pubmed, doi:10.1177/1177271917726964.

Published In

Biomark Insights

DOI

ISSN

1177-2719

Publication Date

2017

Volume

12

Start / End Page

1177271917726964

Location

United States

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3205 Medical biochemistry and metabolomics
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1101 Medical Biochemistry and Metabolomics